

SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 07/18/17

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Reduce the risk of major adverse cardiac events (MACE) in patients with Chronic Heart Failure and significant Coronary Artery Disease (2)	Phase III	
		Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts (2)	Phase III	
		Secondary prevention of stroke in patients who have experienced Embolic Stroke of undetermined source (ESUS) (2)	Phase III	
		Reduce the risk of MACE in patients with coronary or Peripheral Artery Disease (2)	Phase III	
		VTE prophylaxis in ambulatory cancer patients receiving chemo at high-risk for VTE (2)	Phase III	
		Long-term Prevention of Recurrent Symptomatic VTE (2)	Filed 4/17	
		Infrainguinal revascular (2)	Phase III	
	INVOKANA® (canagliflozin)	Diabetic Nephropathy (2) Reduce the risk of death in type 2 diabetes with established, or risk for, cardiovascular disease. (CANVAS /CANVAS-R) (2)	Phase III Phase III/IV	Phase III Phase III/IV
Immunology	TREMFYA™ (guselkumab)	Moderate to Severe Plaque Psoriasis	Approved 7/17	Filed 11/16
	SIMPONI® ARIA™ (golimumab)	Ankylosing spondylitis Psoriatic arthritis Juvenile Idiopathic Arthritis (JIA)	Filed 12/16 Filed 12/16 Phase III	
	sirukumab	Rheumatoid Arthritis (2)	Filed 9/16	Filed 9/16
	STELARA® (ustekinumab)	Pediatric Psoriasis Ulcerative Colitis	Filed 12/16 Phase III	Approved 6/15 Phase III
Infectious Diseases and Vaccines	DARUNAVIR STR (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)	Single tablet regimen for HIV in treatment naïve patients and treatment experienced patients (2)	Phase III	Filed 9/16
	EDURANT® STR (rilpivirine and dolutegravir)	Single tablet regimen for HIV in treatment experienced patients (2)	Filed 6/17	Filed 5/17
	Rilpivirine Long Acting nanosuspension for injection	HIV Infection	Phase III	Phase III
	cadazolid	Clostridium difficile-associated diarrhea (2)	Phase III	Phase III
Neuroscience	esketamine	Treatment-resistant depression Major depressive disorder with imminent risk for suicide	Phase III Phase III	Phase III Phase III
	ponesimod	Relapsing multiple sclerosis (2)	Phase III	Phase III
Oncology	DARZALEX®	Relapsed/refractory multiple myeloma in combination with lenalidomide/dexamethasone (MMY3003) (2)	Approved 11/16	Approved 4/17
		Relapsed/refractory multiple myeloma in combination with bortezomib/dexamethasone (MMY3004) (2)	Approved 11/16	Approved 4/17
		Frontline multiple myeloma transplant eligible in combination with bortezomib, thalidomide and dexamethasone (MMY 3006) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible patients in combination with bortezomib, melphalan, and prednisone (MMY 3007) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY 3008) (2)	Phase III	Phase III
		Relapsed Refractory MM w/PomDex (2)	Approved 6/17	Phase III
		Relapsed Refractory MM w/carfilzomib/dex (Amgen sponsored) (2)	Phase III	Phase III
	IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
		Relapsed/refractory patients with Indolent Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III
		Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma in combination with R-CHOP (randomized study DBL3001) (2)	Phase III	Phase III
		Previously Treated Adults with Waldenstrom's Macroglobulinemia with Rituximab (PCYC-1127) (2)	Phase III	Phase III
		Frontline Chronic Lymphocytic Leukemia (Young and Fit) (in combination with Rituximab) (ECOG 1912) (2)	Phase III	Phase III
		Chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy (2)	Filed 2/17	
		Frontline Chronic Lymphocytic Leukemia in combination with obinutuzumab (PCYC-1130) (2)	Phase III	Phase III
	apalutamide (ARN-509)	Prostate cancer pre-metastatic castration-resistant	Phase III	Phase III
		Metastatic hormone sensitive prostate cancer	Phase III	Phase III
		Localized prostate cancer	Phase III	Phase III
apalutamide (ARN-509)/ ZYTIGA® (abiraterone acetate)	Prostate Cancer metastatic castration resistant chemotherapy naïve	Phase III	Phase III	
	AML frontline not fit for chemo (2)	Phase III	Phase III	
talacotuzumab (CSL362)	AML frontline not fit for chemo (2)	Phase III	Phase III	
YONDELIS® (trabectedin)	Relapsed Ovarian Cancer (2)	Phase III		
ZYTIGA® (abiraterone acetate)	Prostate Cancer Newly Diagnosed Hormone Naïve Metastatic		Filed 4/17	

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; PREZISTA STR and EDURANT STR (R/F/TAF) developed in collaboration with Gilead Sciences; EDURANT STR developed in collaboration with Viiv Healthcare; YONDELIS developed in collaboration with PharmaMar S.A.; Talacotuzumab licensed from CSL Limited XARELTO co-developed with Bayer HealthCare; INVEGA SUSTENNA includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacylics, LLC, an AbbVie company; Sirukumab developed in collaboration with GlaxoSmithKline; Ponesimod and Cadazolid developed by Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson

Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
 Selective Highlights as of July 18, 2017

NMEs APPROVED 2016/2017	NMEs IN REGISTRATION	NME PLANNED FILINGS 2017-2021*	
Oncology	Immunology	Oncology	Neuroscience
DARZALEX® (daratumumab) Double Refractory multiple myeloma	Sirukumab Rheumatoid arthritis	Apalutamide (ARN-509) Pre-metastatic prostate cancer	Esketamine Treatment resistant depression
Immunology		Imetelstat Myelofibrosis	Seltorexant (JNJ-7922) Adjunctive treatment for major depressive disorder
TREMFYA™ (guselkumab) Psoriasis		Erdafitinib (FGFR1 kinase inhibitor) Urothelial cancer	Ponesimod Relapsing multiple sclerosis
		Talacotuzumab (CSL362) AML frontline not fit for chemo	Infectious Diseases & Vaccines
		Niraparib Metastatic castration-resistant prostate cancer (mCRPC)	Lumicitabine (JNJ-1575) RSV infection
			VAC18193 (RSV vaccine) RSV elderly
			JNJ-1860 (ExPEC vaccine) Bacterial infection
			JNJ-4178 (3DAA) HCV
			Pimodivir (JNJ-3872) Influenza A

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Sirukumab developed in collaboration with GlaxoSmithKline; DARZALEX licensed from Genmab A/S; YONDELIS developed in collaboration with Pharma Mar S.A.; Seltorexant (Orexin -2) antagonist codeveloped with Minerva Neurosciences; Imetelstat licensed from Geron; Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; Talacotuzumab licensed from CSL Limited; Erdafitinib discovered in collaboration with Astex Pharmaceuticals, Inc.; Ponesimod developed by Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson

